Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 79

1.

A recurrent splicing variant without c-ABL Exon 7 in Imatinib-resistant patients.

Curvo RP, Zalcberg IR, Scholl V, Pires V, Moellmann-Coelho A, Moreira MA.

Leuk Res. 2008 Mar;32(3):508-10. Epub 2007 Jun 13. No abstract available.

PMID:
17570524
[PubMed - indexed for MEDLINE]
2.

Supplemental results of the detection of splicing variant with c-ABL exon 7 deletion by direct sequencing Comment on "A recurrent splicing variant without c-ABL Exon 7 in Imatinib-resistant patients" by Curvo et al. [Leuk. Res.].

Cho EH, Kang SK, Kim SY.

Leuk Res. 2009 Mar;33(3):505-6. doi: 10.1016/j.leukres.2008.08.024. Epub 2008 Oct 9. No abstract available.

PMID:
18848355
[PubMed - indexed for MEDLINE]
3.

Double Philadelphia-chromosome: a resistance factor on the imatinib mesylate therapy for chronic myeloid leukemia.

Otero L, Ornellas MH, Dobbin J, de Souza Fernandez T.

Int J Lab Hematol. 2008 Aug;30(4):346-8. doi: 10.1111/j.1751-553X.2007.00957.x. No abstract available.

PMID:
18665834
[PubMed - indexed for MEDLINE]
4.

Characterization of ABL exon 7 deletion by molecular genetic and bioinformatic methods reveals no association with imatinib resistance in chronic myeloid leukemia.

Meggyesi N, Kalmár L, Fekete S, Masszi T, Tordai A, Andrikovics H.

Med Oncol. 2012 Sep;29(3):2136-42. doi: 10.1007/s12032-011-0092-9. Epub 2011 Oct 30.

PMID:
22038725
[PubMed - indexed for MEDLINE]
5.

Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain.

Stagno F, Vigneri P, Del Fabro V, Stella S, Massimino M, Berretta S, Cupri A, Consoli C, Messina L, Tirrò E, Messina A, Di Raimondo F.

Leuk Res. 2009 Sep;33(9):e157-8. doi: 10.1016/j.leukres.2009.03.040. Epub 2009 Apr 29. No abstract available.

PMID:
19406471
[PubMed - indexed for MEDLINE]
6.

Mutational analysis and overcoming imatinib resistance in chronic myeloid leukemia with novel tyrosine kinase inhibitors.

Mauro MJ.

Curr Treat Options Oncol. 2007 Aug;8(4):287-95. Review. No abstract available.

PMID:
18157514
[PubMed - indexed for MEDLINE]
7.

Imatinib resistance in CML.

Volpe G, Panuzzo C, Ulisciani S, Cilloni D.

Cancer Lett. 2009 Feb 8;274(1):1-9. doi: 10.1016/j.canlet.2008.06.003. Epub 2008 Jul 23. Review.

PMID:
18653275
[PubMed - indexed for MEDLINE]
8.

New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.

O'Hare T, Eide CA, Deininger MW.

Expert Opin Investig Drugs. 2008 Jun;17(6):865-78. doi: 10.1517/13543784.17.6.865 . Review.

PMID:
18491988
[PubMed - indexed for MEDLINE]
9.

Chronic myelogenous leukemia progenitors display a genetically unstable personality.

Rodrigues MS, Sattler M.

J Natl Cancer Inst. 2007 May 2;99(9):662-3. No abstract available.

PMID:
17470729
[PubMed - indexed for MEDLINE]
Free Article
10.

Coexistence of AML1/RUNX1 and BCR-ABL point mutations in an imatinib-resistant form of CML.

Corm S, Biggio V, Roche-Lestienne C, Laï JL, Yakoub-Agha I, Philippe N, Nicolini FE, Facon T, Preudhomme C.

Leukemia. 2005 Nov;19(11):1991-2. No abstract available.

PMID:
16151468
[PubMed - indexed for MEDLINE]
11.

BCR-ABL in chronic myelogenous leukemia--how does it work?

Goldman JM, Melo JV.

Acta Haematol. 2008;119(4):212-7. doi: 10.1159/000140633. Epub 2008 Jun 20. Review.

PMID:
18566539
[PubMed - indexed for MEDLINE]
12.

Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.

Ernst T, Erben P, Müller MC, Paschka P, Schenk T, Hoffmann J, Kreil S, La Rosée P, Hehlmann R, Hochhaus A.

Haematologica. 2008 Feb;93(2):186-92. doi: 10.3324/haematol.11993. Epub 2008 Jan 26.

PMID:
18223278
[PubMed - indexed for MEDLINE]
Free Article
13.

Varying response to escalating the dose of imatinib in patients with CML who "acquire" a BCR-ABL M244V mutant allele.

Anand M, Khorashad J, Marin D, Apperley JF, Goldman JM, Kaeda JS.

Blood. 2006 Oct 15;108(8):2881-2. No abstract available.

PMID:
17021308
[PubMed - indexed for MEDLINE]
Free Article
14.

Imatinib mesylate resistance in a chronic myeloid leukemia patient with a novel e8a2 BCR-ABL transcript variant.

Qin YZ, Jiang B, Jiang Q, Zhang Y, Jiang H, Li JL, Zhu HH, Li LD, Liu YR, Chen SS, Huang XJ.

Acta Haematol. 2008;120(3):146-9. doi: 10.1159/000178145. Epub 2008 Nov 28.

PMID:
19039205
[PubMed - indexed for MEDLINE]
15.

Imatinib resistance in a novel translocation der(17)t(1;17)(q25;p13) with loss of TP53 but without BCR/ABL kinase domain mutation in chronic myelogenous leukemia.

Yamamoto K, Yakushijin K, Nishikawa S, Minagawa K, Katayama Y, Shimoyama M, Matsui T.

Cancer Genet Cytogenet. 2008 May;183(1):77-81. doi: 10.1016/j.cancergencyto.2008.01.024.

PMID:
18474303
[PubMed - indexed for MEDLINE]
16.

Duplication of the Ph-chromosome as a possible mechanism of resistance to imatinib mesylate in patients with chronic myelogenous leukemia.

Ossard-Receveur A, Bernheim A, Clausse B, Danglot G, Fauvet D, Leon B, Lozach F, Bories D, Brouzes C, Bourhis JH, Turhan AG.

Cancer Genet Cytogenet. 2005 Dec;163(2):189-90. No abstract available.

PMID:
16337868
[PubMed - indexed for MEDLINE]
17.

Suitability of the PAXgene system to stabilize bone marrow RNA in imatinib-resistant patients with chronic myeloid leukemia.

Ernst T, Hoffmann J, Erben P, Hehlmann R, Hochhaus A, Müller MC.

Clin Chem Lab Med. 2008;46(3):318-22. doi: 10.1515/CCLM.2008.086.

PMID:
18303987
[PubMed - indexed for MEDLINE]
18.

Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases.

Vefring HK, Gruber FX, Wee L, Hovland R, Hjorth-Hansen H, Gedde Dahl T, Meyer P.

Acta Haematol. 2009;122(1):11-6. doi: 10.1159/000230037. Epub 2009 Jul 29.

PMID:
19641300
[PubMed - indexed for MEDLINE]
19.

D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients.

Leguay T, Desplat V, Marit G, Mahon FX.

Leukemia. 2005 Dec;19(12):2332-3; author reply 2333-4. No abstract available.

PMID:
16281074
[PubMed - indexed for MEDLINE]
20.

Monosomy 7 in t(9;22)-negative cells during nilotinib therapy in an imatinib-resistant chronic myeloid leukemia case.

Zeidan A, Kakati S, Anderson B, Barcos M, Wetzler M.

Cancer Genet Cytogenet. 2007 Jul 15;176(2):169-71. No abstract available.

PMID:
17656263
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk